Neuromedical

Neuromedical occupies a specialized medical-device and neurotechnology niche, with a broad company description centered on electro-stimulating equipment for clinical and therapeutic use and a more specific stated interest in vagus nerve stimulation for Alzheimer’s disease. That combination suggests an intended distinction from general medical-equipment suppliers: the company’s positioning emphasizes neuromodulation and a neurodegenerative-disease application rather than equipment distribution alone. Its listed categories—Medical, Medical Device, and Wholesale—also span both product technology and supply activity, making the precise competitive set unclear. The company’s small indicated employee range of 1–10 and total structured funding of $801,239 point to a comparatively small operation, not evidence of scale against established device manufacturers. Its closed operating-status listing further complicates any assessment of current market participation.

Neuromedical’s visible financing history has two dated seed rounds: INNOventure participated in the May 17, 2020 round, whose amount is undisclosed, and Hard2beat led the May 21, 2025 round of PLN 3 million (approximately $801,239). A separate grant/project-funding figure of PLN 3,348,671.60 is also present, but its date and relationship to the reported seed rounds are unclear; it should not be treated as confirmed incremental equity or added to the structured funding total. The company is listed in the 1–10 employee range, with no hiring news or employee-growth history available. Most importantly, a closed operating-status listing conflicts with the later financing and product positioning.